Crism Therapeutics (STU:A7L) Common Stock: €77.82 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:A7L Crism Therapeutics Corp STU:A7L
37 GF Score
Price €2.24
! 3 Warning Signs
View Full Analysis

What is Crism Therapeutics Common Stock?

Crism Therapeutics STU:A7L 37 Common Stock is €77.82 Mil as of Dec. 2025. GuruFocus rates STU:A7L with a GF Score™ of 37/100. The stock has 3 warning signs investors should review.

Crism Therapeutics's quarterly common stock declined from Dec. 2024 (€79.96 Mil) to Jun. 2025 (€77.91 Mil) and declined from Jun. 2025 (€77.91 Mil) to Dec. 2025 (€77.82 Mil).

Crism Therapeutics's annual common stock increased from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€79.96 Mil) but then declined from Dec. 2024 (€79.96 Mil) to Dec. 2025 (€77.82 Mil).

Crism Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Crism Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crism Therapeutics Common Stock Chart

Crism Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 70.15 76.76 0.00 79.96 77.82

Crism Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 81.52 79.96 77.91 77.82
STU:A7L
37GF Score
Crism Therapeutics Corp STU:A7L
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crism Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €77.82 Mil mean?
Crism Therapeutics (STU:A7L) has a Common Stock of €77.82 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Crism Therapeutics and its competitors.
Is Crism Therapeutics' Common Stock too high?
Crism Therapeutics' current Common Stock is €77.82 Mil. Overall, Crism Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Crism Therapeutics' Common Stock compare to VRTX and REGN?
Crism Therapeutics' Common Stock of €77.82 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Crism Therapeutics and its competitors. Crism Therapeutics's current Common Stock is €77.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crism Therapeutics stock overvalued right now?
Crism Therapeutics (STU:A7L) has a current Common Stock of €77.82 Mil. The current Common Stock is €77.82 Mil. Crism Therapeutics' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Crism Therapeutics (STU:A7L), the current Common Stock is €77.82 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crism Therapeutics Business Description

Other Exchanges CRTX:UK
Address Kingston Chambers, P.O. Box 173, Tortola, Road Town, VGB
Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.
37GF Score

Get the complete analysis for STU:A7L

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.24
Price